ConvEyXO is a pioneering therapeutic company dedicated to unlocking the transformative power of small extracellular vesciles (called “exosomes”). Established in 2019 by a team of seasoned experts in cell therapy, our mission is to democratize access to miRNA-enhanced exosome-based treatments, making them more accessible and affordable for all. Through strategic collaborations, joint ventures, acquisitions, and licensing agreements, we have cultivated a robust intellectual property portfolio of Deep Technologies.

In line with our commitment to therapeutic innovation, we’ve developed a comprehensive therapeutic portfolio focused on anti-inflammatory and degenerative diseases. Among these, osteoarthritis (OA) has been selected as our platform proof-of-concept. However, our ambitions extend far beyond, with ongoing developments in dermatology, kidney and and neurodegenerative diseases.

At ConvEyXO, we focus on bolstering our capabilities in the realm of therapeutic innovation. By integrating breakthrough manufacturing technology (Exo-Harvest) and advanced loading technologies (XomeXBio), we have developed a unique platform poised to revolutionize the production of miRNA-enhanced exosomes on a large scale.

Our commitment to advancing the field of therapeutics drives every aspect of our work, from research and development to commercialization. ConvEyXO is at the forefront of harnessing the therapeutic potential of miRNA-enhanced exosomes to improve health outcomes and enhance the quality of life for patients worldwide.